50609-01-3

Basic information

• Product Name: 4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINE
• Synonyms: 4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINE;4-(2-(PYRROLIDIN-1-YL)ETHOXY)ANILINE;BenzenaMine, 4-[2-(1-pyrrolidinyl)ethoxy]-;4-(2-Pyrrolidinoethoxy)aniline;4-(2-(Pyrrolidin-1-yl)
• CAS NO: 50609-01-3
• Molecular Formula: C₁₂H₁₈N₂O
• Molecular Weight: 206.28412
• Mol File: 50609-01-3.mol
• Article Data: 35

Chemical Properties

• Boiling Point: 362.2°C at 760 mmHg
• Flash Point: 172.9°C
• Appearance: /
• Density: 1.097g/cm³
• Vapor Pressure: 1.96E-05mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.76±0.20(Predicted)
• CAS DataBase Reference: 4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINE(50609-01-3)
• EPA Substance Registry System: 4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINE(50609-01-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 50609-01-3(Hazardous Substances Data)

Usage

General Description

4-(2-Pyrrolidin-1-yl-ethoxy)-phenylamine is a chemical compound with a molecular formula C13H18N2O. It is a phenylamine derivative with a pyrrolidine moiety attached to the phenyl ring through an ethoxy linker. 4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYLAMINE has potential pharmacological properties and may be used in the development of new drugs. It is important to handle and use this chemical with care, following proper safety guidelines and regulations to prevent any potential hazards. Additionally, further research and testing may be necessary to fully understand its properties and potential applications.

InChI:InChI=1/C12H18N2O/c13-11-3-5-12(6-4-11)15-10-9-14-7-1-2-8-14/h3-6H,1-2,7-10,13H2

Upstream product

• 2955-88-6 1-pyrrolidineethanol 
• 350-46-9 4-Fluoronitrobenzene 
• 100-02-7 4-nitro-phenol 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 3383-72-0 1-(2-chloroethoxy)-4-nitrobenzene 
• 16365-27-8 2-(4-nitrophenoxy)ethanol 
• 1081-73-8 1-[2-(4-bromophenoxy)ethyl]pyrrolidine 
• 100-00-5 4-chlorobenzonitrile 
• 123-30-8 4-amino-phenol 
• 85002-96-6 1-(2-(4-nitrophenoxy)ethyl)pyrrolidine hydrochloride 
• 265654-77-1 1-(2-(4-nitrophenoxy)ethyl)pyrrolidine 
• 13288-06-7 1-(2-bromoethoxy)-4-nitrobenzene 

Downstream Products

• 74773-39-0 5-[4-(2-Pyrrolidin-1-yl-ethoxy)-benzyl]-thiazolidine-2,4-dione; hydrochloride 
• 675867-54-6 cyclohexanecarboxylic acid [4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amide 
• 1037533-46-2 C₂₀H₂₂N₄O₂ 
• 38519-92-5 (5-methyl-benzothiazol-2-yl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine 
• 1147015-03-9 1-isopropyl-7-((2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)ethynyl)-1H-indole-3-carbonitrile 
• 1147015-28-8 4-{[2-ethyl-1-(1-methylethyl)-1H-benzimidazol-7-yl]ethynyl}-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-amine 

Relevant articles and documents

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure-activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.

PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY

Pyrazole compounds (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a pyrazole compounds, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Diphenylamino pyrimidine compound for inhibiting kinase activity

The invention provides a diphenylamino pyrimidine compound for inhibiting the kinase activity, and particularly provides a medicinal composition of a substituted diphenylamino pyrimidine compound andapplication thereof. The compound is a compound as shown in a formula (I) in the specification, or pharmaceutically acceptable salt, prodrug, hydrate thereof or solvent compound, crystal form, N-oxideand various diastereomers thereof. The compound can be used for treating diseases which can be treated with JAK2 kinase inhibitors.